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Abstract
Background: A substantial degree of variability in practices exists amongst donor hospitals regarding the donor
detection, determination of brain death, application of donor management techniques or achievement of donor
management goals. A possible strategy to standardize the donation process and to optimize outcomes could lie in
the implementation of a care pathway. The aim of the study was to identify and select a set of relevant key
interventions and quality indicators in order to develop a specific care pathway for donation after brain death and
to rigorously evaluate its impact.
Methods: A RAND modified three-round Delphi approach was used to build consensus within a single country
about potential key interventions and quality indicators identified in existing guidelines, review articles, process flow
diagrams and the results of the Organ Donation European Quality System (ODEQUS) project. Comments and
additional key interventions and quality indicators, identified in the first round, were evaluated in the following
rounds and a subsequent physical meeting. The study was conducted over a 4-month time period in 2016.
Results: A multidisciplinary panel of 18 Belgian experts with different relevant backgrounds completed the three
Delphi rounds. Out of a total of 80 key interventions assessed throughout the Delphi process, 65 were considered
to contribute to the quality of care for the management of a potential donor after brain death; 11 out of 12 quality
indicators were validated for relevance and feasibility. Detection of all potential donors after brain death in the
intensive care unit and documentation of cause of no donation were rated as the most important quality
indicators.
Conclusions: Using a RAND modified Delphi approach, consensus was reached for a set of 65 key interventions
and 11 quality indicators for the management of a potential donor after brain death. This set is considered to be
applicable in quality improvement programs for the care of potential donors after brain death, while taking into
account each country’s legislation and regulations regarding organ donation and transplantation.
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brain death
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Background
Organ transplantation has proven to be lifesaving and to
have improved the quality of life of numerous patients
since the first successful kidney transplant in 1954. As
the standard treatment for end-stage organ failure, organ
transplantation is currently performed in 112 countries
worldwide. In 2015, more than 143,000 patients across
the 47 member states of the Council of Europe were on
waiting lists for a heart, lung, kidney, liver, pancreas or
intestinal transplant. Unfortunately, on average 18 of
them died every day because of lack of timely organ
availability [1]. The majority of transplant procedures
rely on organs from donors after brain death (DBD).
DBDs are more likely to donate multiple transplantable
organs. The maintenance of perfusion and oxygenation
in DBDs creates optimal conditions for successful organ
transplantation.
In order to cope with these transplant needs, the field
of organ donation and transplantation has been forced
to evolve rapidly. Various health care services are re-
quired in this complex care process and therefore an ef-
fective organization and coordination of all involved
health care professionals is essential. Nowadays, in many
European Union member states, donor coordinators
have been appointed in hospitals with an intensive care
unit (ICU), where organ retrieval from deceased donors
can be considered. Donor coordinators have clearly
defined responsibilities in establishing, managing and
reviewing the deceased donation processes in their hos-
pital [2]. To support this, guidelines for the management
of potential donors can provide donor coordinators with
recommendations based on the best available evidence.
However, in spite of efforts to develop standardized guide-
lines, there remains a large degree of variability in prac-
tices amongst hospitals regarding the determination of
brain death, application of donor management techniques
or achievement of donor management goals [3–7]. These
may potentially contribute to under-recruitment of poten-
tial organ donors.
A possible strategy to standardize the donation process
and to optimize outcomes could lie in the implementa-
tion of a validated care pathway. Care pathways are de-
fined by the European Pathway Association as ‘a
complex intervention for the mutual decision making
and organization of care processes for a well-defined
group of patients during a well-defined period’ [8]. They
support the translation of clinical guidelines into local
protocols and introduction into clinical practice [9].
Care pathways are used worldwide for a variety of pa-
tient groups to reduce undesired variability and
standardize care based on the latest evidence [10]. They
have also been developed for donation after brain death,
such as the pathways of the United Network for Organ
Sharing, National Institute for Health and Clinical
Excellence or National Health Service Blood and Trans-
plant [11–13]. However, a recent systematic review on
the effects of existing care pathways for donation after
brain death revealed that only one study effectively eval-
uated the impact of such a care pathway [14].
Typical active ingredients of a care pathway include
the promotion of interdisciplinary teamwork, the inte-
gration of a set of evidence-based key interventions (KI),
and the active follow-up of care processes by a set of
quality indicators (QI) to verify compliance to KIs [15].
KIs are those which are required to guarantee high qual-
ity care, and hence in this setting will have a significant
impact on patient, donor family, recipient or graft
outcomes.
The present study therefore aims at selecting a set of
KIs to be included in a care pathway for donation after
brain death as well as a set of QIs that are relevant to as-
sess the quality of care for potential DBDs and the im-
pact of such a care pathway.
Methods
Study design
To develop a set of relevant KIs and QIs, a RAND modi-
fied Delphi technique [16] was used with a predefined
number of rounds to stop the Delphi process and a
threshold value for consensus [17]. After selection of an
extensive set of KIs and QIs from the literature and
composition of a multidisciplinary expert panel, three
anonymous questionnaire rounds and one physical
meeting were performed to achieve panel consensus
about the relevance of the proposed KIs and relevance
and feasibility of the proposed QIs. Questionnaires were
conducted through LimeSurvey®, an open-source soft-
ware tool to conduct online surveys [18]. E-mail re-
minders were sent at 2 weeks following the initial email
of each round. The consensus procedure took place be-
tween March and June 2016.
Composition of expert panel
The objective was to generate a multidisciplinary Delphi
panel of physicians and nurses involved in the donation
process after brain death in Belgium in order to guaran-
tee relevance for clinical practice and generalizability of
results [17, 19]. The main eligibility criteria consisted of
a longstanding experience in the field of organ donation,
preferably for a minimum of 10 years, and a minimum
of 3 organ donors throughout 2015 in the donor hos-
pital, in which the expert was professionally active.
All Belgian donor coordinators (n = 196), the board
members of the Belgian Society of Intensive Care Medi-
cine (n = 8), and the members of the Transplant Coordi-
nators Section (n = 28) and the Belgian Organ
Procurement Committee (n = 19) of the Belgian Trans-
plantation Society were invited to join this study by an
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information letter (Additional file 1) sent by e-mail by
the first author (PH), describing the criteria required to
be involved in this Delphi panel.
Selection of key interventions and quality indicators
The selection of KIs and QIs consisted of 8 steps: (1)
Delphi questionnaire preparation with extraction of KIs
and QIs, (2) first Delphi round, (3) data analysis of the
first round, (4) second Delphi round, (5) data analysis of
the second round, (6) third Delphi round, (7) data ana-
lysis of the third round, and (8) physical consensus
meeting.
Step 1: Delphi questionnaire preparation with extraction of
key interventions and quality indicators
To develop a Delphi questionnaire including all possible
relevant and feasible KIs and QIs, an extensive literature
review was conducted by the first author (PH). For the re-
view of guidelines on the management of a potential DBD,
the following resources were explored: (I) Websites of na-
tional European transplantation organizations or societies:
Agence de la biomédecine, British Transplantation Soci-
ety, Deutsche Stiftung Organtransplantation, Nederlandse
Transplantatie Stichting, NHS Blood and Transplant, and
Organización Nacional de Trasplantes; (II) Websites of
European transplantation or intensive care medicine orga-
nizations or societies: European Directorate for the Qual-
ity of Medicines and HealthCare, European Society of
Intensive Care Medicine, European Society of Organ
Transplantation, Eurotransplant, and Scandiatransplant;
(III) Websites of international transplantation societies:
International Liver Transplantation Society, International
Transplant Nurses Society, The International Society for
Heart & Lung Transplantation, and The Transplantation
Society; (IV) Public resources for evidence-based clinical
practice guidelines: Guidelines International Network, Na-
tional Guideline Clearinghouse, National Institute for
Health and Clinical Excellence, and Scottish Intercollegi-
ate Guidelines Network; (V) Process flow diagrams based
on evidence-based medicine: Map of Medicine and Na-
tional Institute for Health and Clinical Excellence; and
(VI) Electronic databases: MEDLINE, CINAHL and
EMBASE.
For the first 5 resources, the following search terms
were used: ‘organ donation’ and ‘brain death’. For the elec-
tronic database MEDLINE, the Medical Subject Headings
(MeSH) terms ‘brain death’, ‘donor selection’, ‘tissue and
organ harvesting’, ‘tissue and organ procurement’ or ‘tissue
donors’ were used in combination with ‘guideline’ or ‘prac-
tice guideline’, both as publication type. The strategy was
translated for the other databases. Search limit parameters
included: (I) published between 2009 and 2015, and (II)
written in English, Dutch or French.
Only few of these guidelines included KIs for donor
management [20–22]. Therefore, an additional search
was performed in the electronic databases, MEDLINE,
CINAHL, EMBASE and The Cochrane Library, to in-
clude recent review articles, using the search term
‘donor management’. In addition to the QIs listed in the
guidelines and review articles, the QIs identified in the
organ donation process of the Organ Donation Euro-
pean Quality System (ODEQUS) project were also ana-
lyzed. These were developed by a consortium involving
associated and collaborating partners from 16 European
countries [23].
A two-phase screening evaluation of publications from
these resources was applied. In the first phase, publica-
tions were appraised for relevance based on appropriate-
ness of the title and abstract. If relevance was unclear, or
if the abstract was unavailable, the full text of these pub-
lications was assessed. In the second phase, the full text
of the selected guidelines or process flow diagrams were
reviewed. Following inclusion criteria were applied: (I)
descriptions of KIs or QIs regarding an adult patient
with a devastating brain injury or lesion with evolution
to imminent brain death until post procurement, and
(II) underpinning by in-text references of evidence to
support their practice. The guidelines selected after full
text review were appraised using the validated AGREE
II-Global Rating Scale (AGREE II-GRS) quality assur-
ance tool for clinical practice guidelines. This instrument
consists of 4 items assessing the quality of guideline
reporting. Each item is scored on a seven-point scale
[24]. Guideline quality was independently rated by three
reviewers (PH, KV and PF). A consensus meeting was
held between these reviewers to determine the mean
score of the overall guideline quality. Disagreements be-
tween reviewers during quality rating were resolved
through discussion until consensus was reached. Only
clinical practice guidelines with a mean score of 5–7
points on the overall guideline quality were included.
After the extensive literature review, potential KIs
and QIs were selected by PH, EH and PF. These KIs
and QIs were integrated in an internet-based Delphi
questionnaire, consisting of three main parts: demo-
graphic questions (name and type of hospital or
organization, number of intensive care beds, number
of organ donors, professional group, function, years of
experience in organ donation, age and gender), KIs
and QIs. The demographic questions are included in
the Additional file 1. The provisional Delphi question-
naire was pretested by three intensivists, who were
not eligible to participate in the expert panel.
Step 2: Delphi round 1
During the first round, the participants received an e-mail
with a link to the internet-based Delphi questionnaire. In
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addition to the demographic information, experts were
asked to provide comments on the listed KIs and QIs or
add new ones.
Step 3: Data analysis of Delphi round 1
Based on the comments in Delphi round 1, adjustments
with regard to the description of the KIs and QIs were
made and KIs or QIs were deleted. Newly identified KIs
or QIs suggested by the expert panel were included in
the questionnaire.
Step 4: Delphi round 2
In preparation for the second round, the participants re-
ceived feedback of all the first-round panel members’
comments, deleted KIs and QIs, and the additionally
proposed KIs and QIs. In the first part of the second
Delphi round, experts were asked to rate on a 9-point
Likert rating scale (score 1 indicating “strongly disagree”;
score 9 “strongly agree”), to what extent each KI would
contribute to the quality of care for the management of
a potential donor (or the donor family, recipient or graft)
and similarly to which extent each QI could be consid-
ered relevant and/or feasible to be implemented. The
KIs & QIs of the Delphi round 2 are presented in the
Additional file 1.
Step 5: Data analysis of Delphi round 2
The results of the second round were analyzed using
predefined consensus criteria based on a systematic re-
view about the use and reporting of the Delphi method
for selecting health care QIs [17]. A KI was considered
valid if it had a median score of 7 or more with 75% or
more of the ratings in the highest tertile (Likert score:
7–9). A QI was accepted with agreement if the attribute
relevance had a median score of 7 or more with 75% or
more of the ratings in the highest tertile (Likert score:
7–9) and the attribute feasibility had a median score of 7
or more.
Step 6: Delphi round 3
In round 3, feedback on the quantitative panel results
was provided to all members of the panel, presented by
the following summary statistics: central tendencies (me-
dian, minimum, maximum, and mode), frequency of rat-
ings in each tertile Likert category (1–3, 4–6, and 7–9),
rating of contribution (ratio of “sum of ratings on the
intervention given by participants” to “sum of ratings on
the intervention if all respondents rated the interven-
tions as ‘strongly agree’”), and the respondent’s own re-
sponses. Using this information, respondents were asked
to re-rate the KIs and QIs in case they would like to
change their previous answers.
Step 7: Data analysis of Delphi round 3
The same predefined consensus criteria as in step 5 were
applied to the analysis of the results of the third Delphi
round. If participants of round 2 did not respond in
round 3, their answers of round 2 were considered as
final.
Step 8: Physical consensus meeting
A face-to-face consensus meeting (June 2016) was orga-
nized to discuss and re-rate the KIs and QIs without
consensus after the third round [17]. The nominal group
technique was used as consensus method [25]. One au-
thor (DV) moderated this meeting in order to contain
the influence of dominant personalities. Another author
(PH) presented the available literature concerning the
‘no consensus’ KIs and QIs. Subsequently, the experts
had the possibility to discuss the literature, followed by
the opportunity for re-rating previous individual scores
using the same Likert rating scale.
Results
Delphi panel participants’ characteristics
A total number of 20 eligible experts agreed to partici-
pate in this study. The expert panel had an average of
18-year experience in the field of organ donation (Table 1
for more detailed characteristics of the expert panel). In
round 1, 18 of 20 invited experts completed the ques-
tionnaire. All 18 participants completed the three Delphi
rounds. The physical meeting was attended by 9 experts.
Development of Delphi questionnaire
The literature research initially revealed 12 guidelines, 9
process flow diagrams, and 1719 digital records from the
electronic medical databases. After screening and assess-
ment for eligibility and quality appraisal of full-texts, 10
guidelines [20–22, 26–32] and 9 process flow diagrams
[33–41] were included (Fig. 1). In addition, several re-
view articles [42–49] and the results of the ODEQUS
project [23] were also included.
Based on the review of the literature, 77 potential KIs
and 12 QIs were selected by PH, EH and PF. The KIs were
distributed into 10 domains: (I) detection outside the ICU
and communication to the ICU (n = 1); (II) detection in-
side the ICU and notification to a transplant center (n =
12); (III) donor evaluation and characterization (n = 15);
donor management: (IV) general care (n = 7), (V) moni-
toring (n = 20), (VI) cardiovascular management (n = 5),
(VII) respiratory management (n = 6), (VIII) renal and
electrolyte management (n = 5), (IX) hormone substitution
(n = 3); and (X) post procurement care (n = 3). The QIs
were distributed into 3 domains: (I) structure (n = 5), (II)
process (n = 5), and (III) outcome indicators (n = 2)
respectively.
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Results of the key interventions
Based on the comments in Delphi round 1, some adjust-
ments with regard to the description of some of the 77 KIs
were made and 2 KIs were deleted: ‘request to a transplant
center to perform a liver biopsy in case of hepatic steatosis
and ship it to a transplant center for evaluation by a path-
ologist’ (donor evaluation and characterization) and ‘central
venous pressure monitoring, which is used as a dynamic
measure to assess volume status or fluid responsiveness’
(donor management: monitoring). There were 5 newly
identified KIs suggested by the expert panel, presented in
Table 2 and Additional file 2. These additional interven-
tions were situated within the topics: ‘donor evaluation
and characterization’, ‘donor management: cardiovascular
management and hormone substitution’, and ‘post
procurement’.
In the second and third round, the experts could rate
the now 80 KIs. The full Delphi panel of 18 experts
reached consensus for 65 of the 80 KIs after the third
round (data given in Table 2 with their respective Likert
ratings). These interventions were considered to contrib-
ute to the quality of care for the management of a poten-
tial donor (or the donor family, recipient or graft).
Because not all the experts could attend the physical
meeting after round 3, the results about these 65 KIs with
Likert weighted consensus were considered as the final re-
sults of this Delphi survey.
The 15 KIs without consensus after the third round are
displayed in the Additional file 2. In the physical meeting,
after discussion of the literature, 9 experts reached con-
sensus about 4 out of the remaining 15 KIs without con-
sensus after the third round: (I) Continue an appropriate
prescription of deep venous thrombosis prophylaxis: low
molecular weight heparin (donor management: general
care); (II) Periodically re-assess cuff pressure to check if
there is no cuff leak and if cuff pressure is between 20 and
30 cm H2O to avoid aspiration; (III) Ensuring coagulation
screening or thromboelastography to target therapy if there
is a clinically relevant bleeding; and (IV) Monitoring of gly-
cemic status to target blood glucose ≤ 180 mg/dL (donor
management: monitoring). The main reasons for not
selecting certain KIs after the third round and physical
meeting, as described by the experts, were low level of evi-
dence, the prior inclusion in standard ICU care, conflict-
ing evidence, or rather qualification as an additional
intervention rather than a KI.
Results of the quality indicators
The expert panel did not suggest new QIs or adjustments
to the 12 QIs in the first Delphi round. The full Delphi
panel of 18 experts reached consensus for 11 of 12 QIs (4
structure, 5 process and 2 outcome indicators) after the
third round. In parallel with the KIs, the results about
these 11 QIs with Likert weighted consensus were consid-
ered as the final results of the Delphi survey (Table 3).
The QI without consensus after the third round is in-
cluded in Additional file 2 and was not withheld in the
physical meeting.
Discussion
To our knowledge, this is the first report on the selection of
a set of KIs that can be used for the clinical content of a
care pathway for donation after brain death. A set of 65 KIs
was developed as relevant to quality of care. These inter-
ventions cover the complete organ donation pathway, in-
cluding donor detection, brain death determination, family
approach, donor evaluation and characterization, donor
management, and the post procurement phase. Further-
more, to assess the quality of care for potential DBDs and
the impact of this care pathway, a set of 11 QIs was vali-
dated for the attributes relevance and feasibility. To include
recent data of studies, a continuous monitoring and
Table 1 Characteristics of the Delphi panel (n = 18)
Characteristics n (%)
Gender
Male 9 (50)
Female 9 (50)
Age (years)
30–49 7 (39)
50–69 11 (61)
Professional group
Medical doctor 11 (61)
Nurse 6 (33)
Other 1 (6)
Functions
Intensive care medicine 11 (33)
Anesthesiology 2 (6)
Intensive care nursing 4 (12)
Donor coordination 13 (39)
Transplant coordination 3 (9)
Years of experience
5–9 2 (11)
10–19 7 (39)
20–29 9 (50)
Number of organ donors after brain death and circulatory death in 2015
3–5 4 (22)
6–9 5 (28)
10–25 9 (50)
Type of institution
Academic hospital 12 (67)
Non-academic community hospital 6 (33)
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updating process of this set of KIs and QIs and the result-
ing donor pathway is obviously needed.
While several guidelines, review articles, and process
flow diagrams for the management of a potential donor
have been published, there remains a lack of high qual-
ity evidence to guide clinical practice. The recommen-
dations are largely based on physiological rationale on
the one hand and, consensus statements that over-
whelmingly comprised observational studies and retro-
spective case series on the other hand. This represents
low-quality evidence, with a lack of randomized con-
trolled trials [42, 46]. Remarkably however, only 15 of
the 80 KIs after the third Delphi round were considered
as not valid nor relevant by the expert panel, so consen-
sus was reached for most interventions. This implies
that the KIs selected out of the literature are reasonably
well in agreement with the opinions of our expert
panel, representing a “mainstream” of expert opinion.
The Delphi procedure is an accepted methodology for
the selection of KIs and QIs in health care. This
Fig. 1 Selection of guidelines and process flow diagrams
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Table 2 Results of the 65 key interventions for which consensus was reached by the overall panel after the third Delphi round
Based on literature (L)
or expert panel (E)
Median Tertile 7–9 (%) Tertile 7–9 (n) Rating of
contribution*
Detection outside the ICU & communication to the ICU
Detection of a patient with a devastating brain injury or
lesion with evolution to imminent brain death (for example
intracranial hemorrhage, trauma, cerebral ischemia etc.) on
a unit outside the ICU (for example emergency services,
stroke units, etc.) and early communication of the presence
of this patient to the ICU physician (and referral to the ICU).
L 8 89% 16 87%
Detection inside the ICU & notification to a transplant center
Detection of a potential donor after brain death inside the ICU.
Detection should be based on defined clinical triggers in
patients who have had a devastating brain injury or lesion,
while recognizing that clinical situations vary
˗ A Glasgow Coma Scale score of 4 or less that is not
explained by sedation and
˗ The absence of one or more cranial nerve reflexes
Unless there is a clear reason why the above clinical triggers
are not met and/or a decision has been made to perform
brainstem death tests, whichever is the earlier.
L 9 100% 18 94%
Notification of the donor coordinator at the time these criteria
are met.
L 9 94% 17 91%
Assessment of the prerequisites prior to the clinical evaluation
of brain death:
˗ Coma, irreversible, and cause known.
˗ Neuroimaging compatible with coma.
˗ Central nervous system depressant drug effect absent
(if indicated, toxicology screen; if barbiturates given, serum
level < 10 μg/mL).
˗ No evidence of residual paralytics (electrical stimulation
if paralytics used).
˗ Absence of severe acid-base, electrolyte, and endocrine
abnormality.
˗ Normothermia or mild hypothermia (core temperature >
36 °C).
˗ Systolic blood pressure > 100 mmHg. Vasopressors
may be required.
˗ No spontaneous respiration.
L 8 89% 16 83%
Approaching the family:
˗ Delivering bad news about the hopeless, medical situation.
˗ Support of the family (physician, nurse, social assistant,
psychologist, pastoral service…).
L 9 100% 18 93%
Notification of the potential donor after brain death by an ICU
physician to a transplant center:
˗ Briefing: name, date of birth, diagnosis & therapy, short
medical and behavioral history, etc.
˗ Check the medical contra-indications for organ and tissue
donation on file with the transplant center.
˗ Is there a registration in the National Register, checked
by the transplant center?
L 9 89% 16 91%
Determination of brain death. L 9 100% 18 95%
Legal declaration of death: registration of time of death and
the way in which it is determined on a dated and signed
official report.
L 9 89% 16 93%
Notification of legal authorities if the cause of death is
unknown or suspicious.
L 9 89% 16 90%
Informing the family about the diagnosis of brain death. L 9 100% 18 98%
Informing the family about the outcome of the National
Register and the possibility of organ and tissue donation,
preferably in a separated conversation after family
understand and accept the diagnosis of brain death.
L 9 94% 17 94%
Give clear, unambiguous information about the next main L 9 100% 18 96%
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Table 2 Results of the 65 key interventions for which consensus was reached by the overall panel after the third Delphi round
(Continued)
Based on literature (L)
or expert panel (E)
Median Tertile 7–9 (%) Tertile 7–9 (n) Rating of
contribution*
steps about the donation process to the relatives.
Feedback about the approach of the family and legal
authorities (if the cause of death is unknown or suspicious)
and discussion about the necessary investigations for
donor evaluation and characterization to a transplant center.
L 9 89% 16 90%
Donor evaluation and characterization
Interviewing family and/or other relevant sources (e.g. life
partner, cohabitant, caretaker, friend or primary care physician)
to obtain the medical and behavioral history of the potential
donor which might affect the suitability of the organs for
transplantation and imply the risk of disease transmission.
L 8 89% 16 89%
Reviewing medical charts to obtain the medical and behavioral
history of the potential donor which might affect the suitability
of the organs for transplantation and imply the risk of disease
transmission.
L 9 89% 16 93%
Clinical examination of the potential donor. L 9 89% 16 91%
Collect a blood sample and ship it to a transplant center for
appropriate blood tests.
L 9 100% 18 93%
Discuss with a transplant center, the necessity to examine a
blood sample for the determination of ABO, rhesus blood
group or additional laboratory tests.
L 9 83% 15 90%
Collect a urine sample (if not shipped to a transplant center)
for measurement of sediment, protein & glucose.
L 9 83% 15 87%
Perform a chest X-ray, mandatory for each potential donor and
to allow evaluation of a potential lung and/or heart donor.
L 9 89% 16 90%
Discuss with a transplant center, the necessity to perform a
bronchoscopy by an experienced physician to allow evaluation
of a potential lung donor together with a bilateral bronchoalveolar
lavage to collect samples for microbiological tests and to clear
mucous plugs or blood clots that may contribute to impaired
oxygenation.
L 8 78% 14 81%
Perform an arterial blood gas to allow evaluation of a potential
lung donor.
L 9 83% 15 88%
Discuss with a transplant center, the necessity to perform an
arterial blood gas for a potential lung donor after 10 min
ventilation with FiO2 100% & 5 cm H2O PEEP.
L 9 83% 15 89%
Perform a 12 lead ECG to allow evaluation of a potential
heart donor.
L 9 89% 16 90%
Discuss with a transplant center, the necessity to perform a
cardiac ultrasound by an experienced physician to allow
evaluation of a potential heart donor.
L 9 89% 16 89%
Discuss with a transplant center, the necessity to perform,
if possible, a coronary angiography if cardiac ultrasound is
acceptable but other comorbidities are present.
E 8 89% 16 86%
Discuss with a transplant center, the necessity to perform
an abdominal ultrasound (or CT scan) to allow evaluation
of a potential liver, pancreas and/or kidney donor.
L 8 94% 17 88%
Collect the minimum data, as requested by the transplant
center for the characterization of organs and donor, on a
donor information form and send it together with the
results of the investigations to a transplant center.
L 9 100% 18 93%
Donor management: general care
Provide at least an arterial line and a central venous line,
if not present.
L 8 83% 15 86%
Continue appropriate antibiotic therapy and other life L 8 94% 17 90%
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Table 2 Results of the 65 key interventions for which consensus was reached by the overall panel after the third Delphi round
(Continued)
Based on literature (L)
or expert panel (E)
Median Tertile 7–9 (%) Tertile 7–9 (n) Rating of
contribution*
supporting pharmacotherapy, only if indicated.
Use warming mattress, blankets or warmed
intravenous fluids if needed, to prophylactically
prevent hypothermia.
L 8 78% 14 84%
Reduce vasopressors (if possible) while maintaining
hemodynamic stability.
L 9 100% 18 92%
Donor management: monitoring
Monitor the core body temperature.
Target temperature: between 35 and 37 °C.
L 8 100% 18 91%
ECG monitoring of heart rate.
Target heart rate between 60 and 100 beats per
minute.
L 8 78% 14 83%
Repeat a 12-lead ECG for a potential heart donor
if there are subsequent changes in monitored
complexes.
L 8 83% 15 87%
Invasive arterial pressure monitoring.
Target mean arterial pressure: ≥ 60 mmHg.
L 9 94% 17 91%
Ensuring a recent chest X-ray examination for a
potential lung and/or heart donor is available.
L 9 89% 16 90%
Monitoring of ventilator parameters. L 9 94% 17 91%
Peripheral oxygen saturation monitoring (SaO2).
Target SaO2: > 95%.
L 9 83% 15 91%
Perform a blood gas analysis on a regular basis.
Target pH: 7.3–7.5.
Target arterial oxygen tension (PaO2): 80–100 mmHg.
Target arterial carbon dioxide tension (PaCO2): 35–45
mmHg.
L 8 89% 16 88%
Send a bronchial secretion sample for microscopy and
culture if secretions are present.
L 8 89% 16 89%
Perform a bronchoscopy for diagnosis or therapy if
clinically indicated.
L 8 83% 15 88%
Estimate the effective intravascular volume and overall
fluid status by chart review and clinical examination.
L 8 78% 14 81%
Monitor hourly urine output, particularly looking for any
suggestion of the onset of diabetes insipidus (polyuria).
Target urine output: 0.5–3 mL/kg/h.
L 8 89% 16 90%
Measure blood electrolytes on a regular basis.Target
serum sodium: ≤ 155 mEq/L.
L 8 89% 16 87%
Measure routine full blood counts to examine the need
for transfusion of red blood cells if clinically indicated.
Target hemoglobin: > 7 g/dL.
L 8 78% 14 81%
Donor management: cardiovascular management
(hypotension)
Use isotonic crystalloids for intravascular volume
replacement and use blood products and colloids
(albumin) for specific circumstances.
L 8 94% 17 90%
Ensuring an appropriate prescription of vasoactive
drugs when correction of the volume deficit fails to
achieve the threshold hemodynamic goals.
L 9 100% 18 92%
Donor management: cardiovascular management
(bradycardia)
Treat bradycardia causing hemodynamic instability,
with a short acting β-adrenergic agonist
(epinephrine/dopamine/dobutamine/isoprenaline)
L 7 83% 15 81%
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Table 2 Results of the 65 key interventions for which consensus was reached by the overall panel after the third Delphi round
(Continued)
Based on literature (L)
or expert panel (E)
Median Tertile 7–9 (%) Tertile 7–9 (n) Rating of
contribution*
or occasionally transvenous pacing. Don’t use
atropine because bradycardia are the consequence
of high-level vagal stimulation and exhibit a high
degree of resistance to atropine.
Donor management: cardiovascular management
(tachycardia)
Treat tachycardia by following the established
advanced cardiopulmonary life support guidelines.
E 8 89% 16 87%
Donor management: respiratory management
Ensuring a lung protective ventilation is installed:
˗ Minimum FiO2 to obtain a PO2 between 80 and
100 mmHg
˗ Tidal volume (Vt): 6–8 mL/kg (ideal body weight)
˗ Plateau pressure: < 30 cm H2O
˗ PEEP (Positive End Expiratory Pressure): 8–10 cm H2O
L 8 89% 16 85%
Maintain 30–45° head of bed elevation to avoid aspiration. L 8 89% 16 89%
Perform recruitment maneuvers and repeat when indicated. L 8 83% 15 85%
Apply a prescription of oral hygiene every 6 h. L 7 89% 16 84%
Donor management: renal and electrolyte management
(oliguria < 0.5 mL/kg/h)
Treat hypovolemia, hypotension and cardiac dysfunction
and consider diuretic only if needed.
L 9 100% 18 93%
Donor management: renal and electrolyte management
(polyuria > 3 mL/kg/h)
Review the medical history, urinary and blood sample to
exclude secondary polyuria: osmotic (Mannitol, hyperglycemia),
induced (diuretic) or adapted (fluid overload).
L 8 100% 18 90%
Confirm diabetes insipidus: urine specific gravity below
1.005 g/mL or trend towards hypernatremia/hyperosmolarity.
L 8 94% 17 87%
Treat diabetes insipidus with sufficient fluid volume replacement
to compensate polyuria and anti-diuretic hormone replacement.
˗ Fluid volume replacement with monitoring of electrolytes
and blood glucose levels.
˗ Anti-diuretic hormone replacement with desmopressin as
a first line medication.
L 8 100% 18 93%
Donor management: renal and electrolyte management
(electrolyte disturbances)
Treat electrolyte disturbances. L 9 100% 18 93%
Donor management: hormone substitution
Ensuring an appropriate prescription of insulin if treating
hyperglycemia to achieve a target glucose level of 180 mg/dL
or less.
L 8 83% 15 87%
Post procurement care
Detection, registration and reporting of serious adverse events
to the transplant center.
L 9 100% 18 94%
Debriefing by the donor coordinator and/or transplant coordinator
about the results of the transplantation (anonymous) to the relatives,
health care professionals and primary care physician.
L 9 94% 17 93%
Offering, if necessary, support to the relatives, for example by a
feedback conversation after a couple of weeks or information
about associations for relatives.
E 9 94% 17 93%
Debriefing with the involved health care professionals and
transplant coordinator.
E 9 89% 16 90%
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systematic approach is recommended in research areas
hampered by limited evidence to guide clinical practice
and disagreement between experts on its interpretation.
This method combines evidence-based practice with ex-
pert opinion by using a multidisciplinary panel. A large
group of experts across diverse locations and areas of
expertise can be included anonymously, thus avoiding
domination of the consensus process by one or a few
experts. This group facilitation technique is designed to
transform individual opinions of experts into group
consensus. It includes a series of questionnaires or rounds
to gather information and achieve consensus [17, 19, 25].
In this Delphi study, outcomes such as patient and
graft survival, graft function, or acute rejection are not
included [29]. These are valuable variables but are likely
dependent on a number of factors that are not related to
the donation procedure (e.g. recipient characteristics,
organ procurement, and preservation), and thereby pro-
vide less information to guide quality improvements at a
donor hospital. Beside QIs related to organ donation, a
set of transplant QIs can also be identified. Accountabil-
ity of the transplant centers on these transplant QIs, will
not only stimulate the donor hospitals towards more ac-
tive engagements in the field but also increase more
transparency to the general public [50].
This study was restricted to the phase of KIs and QIs
selection. In a next step, further research should explore
which KIs (I) are effectively implemented in practice (ad-
herence), and (II) could be improved. These interven-
tions can then be used as a standard to evaluate the
quality of existing DBD care and in quality improvement
programs. Research should also determine the effect of
these interventions on a set of QIs in order to substanti-
ate progress. To this purpose, the three dimensions of
structure, process and outcome indicators can be used
to assess quality of care [25]. QIs rated as most import-
ant were (I) detection of all potential DBDs in the ICU
and (II) documentation of cause of not proceeding to
donation in potential donors. Reliability and feasibility in
practice of this indicator set needs to be tested in both
low- and high-volume donor hospitals. With these indi-
cators, donor coordinators could evaluate the quality of
the organ donation process at the hospital level.
Our study has several strengths. We used the systematic
RAND modified Delphi method, a common and validated
technique in which scientific evidence is combined with
expert opinion. Our procedure is consistent with the guide-
line of Boulkedid et al. for using and reporting this consen-
sus technique, in which the median number of panel
members was 17 [17]. Our panel was multidisciplinary,
with 18 experts covering 5 different functions: intensive
care medicine, anesthesiology, intensive care nursing, donor
coordination, and transplant coordination. All involved
stakeholders were presented. All the experts completed the
three Delphi rounds, which implies that we had a low
non-response bias, increasing the validity of the results.
These are highly relevant and applicable for clinical teams
managing potential DBDs in different health systems, while
taking into account each country’s legislation and regula-
tions regarding organ donation and transplantation. For
being universally accepted, these KIs and QIs need to be
tested in an international setting.
However, this study has also some limitations. It is un-
certain whether the experts who participated are a true
representation of the potentially available experts with
preferably a minimum of 10 years’ experience and a
minimum of 3 organ donors in 2015. On average, only
32% (n = 31) of the Belgian acute care hospitals (n = 98)
had more than 3 donors in 2012/2013, therefore the ma-
jority of the informed donor coordinators did not meet
the criteria to participate in this study [50]. A second
limitation of this study is the national setting in which
these KIs and QIs were selected. However, international
literature was reviewed and the QIs development of the
ODEQUS project was performed by a multidisciplinary
panel, in which several members have international ex-
perience and expertise on the topic. Another potential
limitation is the attendance of the physical meeting by
only 9 experts because of logistic reasons. However, in
this meeting only the KIs and QIs without consensus
after round 3 were re-rated by the experts present and
the results of this meeting were not included in the final
results of the Delphi survey. Finally, only literature pub-
lished in English, Dutch or French was included in this
study, which may include language bias for example to
Spanish or German literature.
Table 2 Results of the 65 key interventions for which consensus was reached by the overall panel after the third Delphi round
(Continued)
Based on literature (L)
or expert panel (E)
Median Tertile 7–9 (%) Tertile 7–9 (n) Rating of
contribution*
Ensuring the hospitalization invoice of the patient is
excluded of any medical, pharmaceutical or hospital
costs after the determination of brain death and legal
declaration of death.
L 9 94% 17 94%
*rating of contribution = ratio of “sum of ratings on the intervention given by participants” to “sum of ratings on the intervention if all respondents rated the
interventions as ‘strongly agree’”
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Table 3 Results of the 11 quality indicators for which consensus was reached by the overall panel after the third Delphi round
Attribute Median Tertile 7–9 (%) Tertile 7–9 (n)
Structure indicators
1. Existence of donation process procedures. Relevance 9 89% 16
Formula: existence of procedures for all relevant
steps of the donation process?
Feasibility 9 83% 15
2. Existence of a proactive donor detection protocol. Relevance 9 89% 16
Formula: existence of a donor detection protocol? Feasibility 8 72% 13
3. Documentation of key interventions of the donation
process.
Relevance 8 89% 16
Formula: existence of a documentation form with all
relevant key interventions of the donation process?
Feasibility 8 83% 15
4. Seminars on organ donation. Relevance 8 83% 15
Formula: number of organ donation seminars
organized last year?
Feasibility 8 78% 14
Process indicators
5. Detection of all potential donors after brain
death in the ICU.
Relevance 9 94% 17
Formula: number of potential donors after brain
death in the ICU who are referred to the donor
coordinator / number of potential donors after
brain death in the ICU.
Feasibility 8 83% 15
6. Evaluation of donors after brain death. Relevance 9 89% 16
Formula: number of patients declared brain death
in the ICU who have been evaluated as donors in
consult with a transplant center / number of
patients declared brain death in the ICU.
Feasibility 8 78% 14
7. Donor management goals. Relevance 8 83% 15
Formula: number of actual donors after brain
death in the ICU meeting 5 of the 7 donor
management goals prior to organ recovery
(mean arterial pressure: 60–110 mmHg,
number of vasopressors ≤ 1, arterial blood
gas pH: 7.3–7.5, serum sodium: 135–155
mEq/L, blood glucose: ≤ 180 mg/dL, urine
output: ≥ 0.5 mL/kg/h over 4 h, core body
temperature: 35–37 °C) / number of actual
donors after brain death in the ICU.
Feasibility 8 72% 13
8. Documentation of cause of no donation. Relevance 9 94% 17
Formula: number of failed potential donors
in which the cause of no donation is properly
documented / number of failed potential donors.
Feasibility 8 83% 15
9. Documentation of evaluation of potential donors. Relevance 8 83% 15
Formula: number of donors correctly evaluated /
number of donors evaluated.
Feasibility 8 67% 12
Outcome indicators
10. Family objection to organ donation. Relevance 9 89% 16
Formula: number of objections (number of potential
donor after brain death cases with family objection
to organ donation) / number of families interviewed*
(number of potential donor after brain death cases in
which family members are informed about the
possibility of organ donation). *exclusion of donor
cases where the patient’s wishes are known (formal or informal).
Feasibility 8 78% 14
11. Conversion rate in donors after brain death. Relevance 9 78% 14
Formula: number of actual donors after brain death /
number of eligible donors after brain death.
Feasibility 9 78% 14
Hoste et al. BMC Health Services Research  (2018) 18:580 Page 12 of 14
Conclusions
Using a RAND modified Delphi approach, consensus
was reached for a set of 65 KIs for the management of
potential DBDs. To assess quality of care for potential
DBDs and the impact of this care pathway, 11 QIs were
validated for the attributes relevance and feasibility.
These KIs are to be considered as a first description of a
standard bundle of care for potential DBDs, while the
QIs identified can be incorporated into specific quality
improvement programs.
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